Kathmere Capital Management LLC Purchases New Position in Humana Inc. (NYSE:HUM)

Kathmere Capital Management LLC acquired a new position in shares of Humana Inc. (NYSE:HUM) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 456 shares of the insurance provider’s stock, valued at approximately $170,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Pzena Investment Management LLC increased its position in shares of Humana by 538.7% during the second quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider’s stock valued at $866,250,000 after acquiring an additional 1,955,375 shares during the last quarter. Ontario Teachers Pension Plan Board lifted its position in Humana by 11,647.2% during the first quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock valued at $367,342,000 after purchasing an additional 1,050,459 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of Humana by 118.9% during the 2nd quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock worth $532,564,000 after acquiring an additional 774,085 shares during the last quarter. Putnam Investments LLC lifted its stake in Humana by 550.3% during the fourth quarter. Putnam Investments LLC now owns 875,489 shares of the insurance provider’s stock worth $400,808,000 after purchasing an additional 740,858 shares during the last quarter. Finally, Steadfast Capital Management LP purchased a new stake in Humana in the first quarter worth approximately $158,813,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Trading Up 2.1 %

Humana stock opened at $319.57 on Monday. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.70. The company has a market cap of $38.51 billion, a P/E ratio of 19.90, a P/E/G ratio of 2.44 and a beta of 0.50. The business has a 50-day simple moving average of $349.94 and a two-hundred day simple moving average of $344.48. Humana Inc. has a 52-week low of $298.61 and a 52-week high of $530.54.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, topping the consensus estimate of $5.89 by $1.07. Humana had a return on equity of 16.12% and a net margin of 1.53%. The firm had revenue of $29.54 billion during the quarter, compared to analyst estimates of $28.52 billion. During the same period in the prior year, the business posted $8.94 EPS. Humana’s revenue was up 10.4% on a year-over-year basis. Analysts predict that Humana Inc. will post 16.01 EPS for the current year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be given a dividend of $0.885 per share. The ex-dividend date is Monday, September 30th. This represents a $3.54 annualized dividend and a dividend yield of 1.11%. Humana’s payout ratio is 22.04%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on HUM. JPMorgan Chase & Co. upped their price objective on shares of Humana from $332.00 to $396.00 and gave the company a “neutral” rating in a research note on Wednesday, August 21st. TD Cowen raised their price target on Humana from $396.00 to $407.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Oppenheimer raised their price objective on shares of Humana from $370.00 to $400.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. Morgan Stanley began coverage on shares of Humana in a research report on Monday, June 24th. They issued an “equal weight” rating and a $374.00 target price on the stock. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $395.00 price target on shares of Humana in a research report on Friday, September 20th. Thirteen investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $398.70.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.